CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations
Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.
CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.
Viking Therapeutics (VKTX) ha avviato una partnership strategica pluriennale con CordenPharma per lo sviluppo e la produzione del suo candidato farmaceutico GLP-1 VK2735. La collaborazione comprende l'intera catena di approvvigionamento, dalla sostanza attiva al prodotto finito, per formulazioni peptidiche sia sottocutanee che orali.
CordenPharma fornirà la produzione di peptidi su larga scala per la sostanza attiva del farmaco Agonista Dual GLP-1/GIP, insieme ai servizi di riempimento e finitura per la formulazione sottocutanea e la produzione di dosaggi solidi orali. L'accordo sfrutta la rete globale di impianti di produzione di CordenPharma, con ridondanza integrata attraverso più siti di sostanza attiva per garantire una fornitura continua durante l'intero ciclo di vita del prodotto.
Viking Therapeutics (VKTX) ha entrado en una asociación estratégica a largo plazo con CordenPharma para el desarrollo y fabricación de su candidato a fármaco GLP-1 VK2735. La asociación abarca toda la cadena de suministro, desde la sustancia activa hasta el producto terminado, para formulaciones peptídicas tanto subcutáneas como orales.
CordenPharma proporcionará fabricación de péptidos a gran escala para la sustancia activa del fármaco Agonista Dual GLP-1/GIP, junto con servicios de llenado y acabado para la formulación subcutánea y fabricación de dosis sólidas orales. El acuerdo aprovecha la red global de instalaciones de fabricación de CordenPharma, que cuenta con redundancia integrada a través de múltiples sitios de sustancia activa para garantizar un suministro ininterrumpido a lo largo del ciclo de vida del producto.
Viking Therapeutics (VKTX)는 CordenPharma와 함께 GLP-1 약물 후보 VK2735의 개발 및 제조를 위한 다년간의 전략적 파트너십을 체결했습니다. 이 파트너십은 약물 물질에서 약물 제품까지의 전체 공급망을 포함하며, 피하 및 경구 펩타이드 제형 모두를 포함합니다.
CordenPharma는 이중 GLP-1/GIP 수용체 작용제 약물 물질에 대한 대규모 펩타이드 제조를 제공하며, 피하 제형에 대한 채우기 및 마무리 서비스와 경구 고형 제형 제조를 제공합니다. 이 계약은 CordenPharma의 글로벌 제조 시설 네트워크를 활용하며, 여러 약물 물질 사이트를 통해 내장된 중복성을 제공하여 제품 생애 주기 동안 중단 없는 공급을 보장합니다.
Viking Therapeutics (VKTX) a conclu un partenariat stratégique pluriannuel avec CordenPharma pour le développement et la fabrication de son candidat médicament GLP-1 VK2735. Ce partenariat englobe l'ensemble de la chaîne d'approvisionnement, de la substance active au produit fini, pour des formulations peptidiques à la fois sous-cutanées et orales.
CordenPharma fournira une fabrication de peptides à grande échelle pour la substance active du médicament Agoniste Dual GLP-1/GIP, ainsi que des services de remplissage et de finition pour la formulation sous-cutanée et la fabrication de dosages solides oraux. L'accord tire parti du réseau mondial d'installations de fabrication de CordenPharma, offrant une redondance intégrée grâce à plusieurs sites de substances actives pour garantir un approvisionnement ininterrompu tout au long du cycle de vie du produit.
Viking Therapeutics (VKTX) hat eine mehrjährige strategische Partnerschaft mit CordenPharma für die Entwicklung und Herstellung seines GLP-1-Arzneimittelkandidaten VK2735 geschlossen. Die Partnerschaft umfasst die gesamte Lieferkette von der Wirkstoffsubstanz bis zum Arzneimittelprodukt für sowohl subkutane als auch orale Peptidformulierungen.
CordenPharma wird die großtechnische Peptidherstellung für die Wirkstoffsubstanz des Dual GLP-1/GIP-Rezeptor-Agonisten bereitstellen, zusammen mit Abfüll- und Fertigstellungsdiensten für die subkutane Formulierung und die Herstellung von festen oralen Dosierungen. Die Vereinbarung nutzt das globale Netzwerk von Produktionsstätten von CordenPharma, das über integrierte Redundanz durch mehrere Wirkstoffstandorte verfügt, um eine unterbrechungsfreie Versorgung während des gesamten Produktlebenszyklus zu gewährleisten.
- Secured long-term manufacturing partnership for commercial supply of VK2735
- Multiple formulation options (both injectable and oral) increase market potential
- Manufacturing redundancy through multiple sites reduces supply chain risks
- Dependency on single manufacturing partner for entire supply chain
Insights
Viking Therapeutics' partnership with CordenPharma represents a significant supply chain advancement for their GLP-1 drug candidate VK2735. This multi-year agreement provides Viking with end-to-end manufacturing capabilities spanning from peptide API production to finished dosage forms in both injectable and oral formulations.
The strategic value lies in CordenPharma's integrated network of 11 facilities across Europe and North America with built-in redundancy across multiple drug substance sites. This redundancy is particularly important for peptide therapeutics, which require specialized manufacturing expertise and face complex production challenges.
Notably, this partnership addresses both clinical and commercial manufacturing needs, indicating preparation for potential scale-up. The dual-formulation strategy (injectable and oral) could provide flexibility in administration routes - a potential differentiator in the GLP-1 space where patient convenience impacts adoption.
CordenPharma's specialized capabilities in peptide manufacturing, sterile injectables, and oral solid dosage forms align precisely with Viking's requirements for VK2735, a dual GLP-1/GIP receptor agonist. Their 2024 financial year sales of €854 million and 3,000+ employee base suggest substantial manufacturing capacity.
The timing of this partnership suggests Viking is positioning itself to ensure manufacturing readiness as VK2735 progresses through clinical development. Securing manufacturing capacity early removes a critical development hurdle that often challenges biotech companies transitioning from clinical to commercial stages.
This manufacturing partnership strengthens Viking's position in the valuable GLP-1 therapeutic space. By securing an integrated supply chain solution from CordenPharma, Viking addresses a critical commercial readiness component for VK2735, their dual GLP-1/GIP receptor agonist.
The agreement covers both subcutaneous and oral peptide formulations of VK2735, reflecting Viking's dual-format strategy. The oral formulation pathway is particularly noteworthy as oral administration could potentially offer competitive advantages in certain segments of the metabolic disease market.
From an execution standpoint, this partnership reduces several risks:
- Manufacturing scale-up risk - leveraging CordenPharma's established infrastructure
- Supply chain complexity - single partner handling API through finished dosage
- Production continuity - multiple manufacturing sites providing redundancy
While financial terms aren't disclosed, the multi-year nature suggests meaningful resource commitment from both companies. For Viking, this arrangement likely provides manufacturing certainty without the capital expenditure of building internal capacity.
This partnership follows the industry trend of dedicated capacity arrangements in the GLP-1 space, where manufacturing capability has strategic importance. Establishing this relationship signals Viking's preparation for potential commercial-stage operations, though regulatory approval and successful clinical outcomes remain prerequisite milestones.
The partnership with CordenPharma, which generated
- CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.
- CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.
- CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.
CordenPharma is committed to ensuring seamless development and commercialization of Viking Therapeutics' VK2735 drug candidate by leveraging its global network of advanced manufacturing facilities for drug substance, fill-finish and oral solid dosage finished product.
This uniquely integrated capability incorporates CordenPharma's extensive experience in large-scale peptide drug substance, sterile injectable fill-finish, and oral solid dosage manufacturing. With built-in redundancy through multiple drug substance sites across its global facility network, CordenPharma is well-positioned to ensure a secure and uninterrupted supply chain throughout the lifecycle of Viking Therapeutics' VK2735 drug candidate.
Dr. Michael Quirmbach, President & CEO of the CordenPharma Group, comments: "We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for this innovative VK2735 drug candidate. Our global teams are excited to provide true integration of our expertise across the pharma supply chain to meet the increasing demand for GLP-1 peptide therapeutics and ultimately, improve patient outcomes."
About CordenPharma
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.
With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).
The CordenPharma Group is comprised of 11 facilities across
Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cordenpharma-and-viking-therapeutics-sign-long-term-strategic-partnership-for-integrated-supply-of-glp-1-peptides-injectables-and-oral-formulations-302397563.html
SOURCE CordenPharma
FAQ
What is the scope of Viking Therapeutics' (VKTX) partnership with CordenPharma for VK2735?
How will CordenPharma ensure reliable supply of Viking's (VKTX) VK2735 drug candidate?
What formulations of VK2735 will CordenPharma manufacture for Viking Therapeutics (VKTX)?
What type of drug is Viking Therapeutics' (VKTX) VK2735?
